Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898777 | 0.88 | PDE10A (0.47) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| SCHEMBL2913941 | 0.87 | PDE10A (0.61) | PDE10ACYSLTR1CYP1A2CYSLTR2CYP3A4 | |
| SCHEMBL9598037 | 0.86 | CYSLTR1 (0.46) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| Hydrochloric Acid SCHEMBL29127709 | 0.86 | PDE10A (0.46) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| SCHEMBL1783030 | 0.85 | CYSLTR1 (0.45) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| SCHEMBL11028869 | 0.85 | CYSLTR1 (0.45) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| SCHEMBL12603960 | 0.85 | CYSLTR1 (0.45) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| SCHEMBL12603937 | 0.85 | CYSLTR1 (0.45) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| SCHEMBL9186483 | 0.85 | CYSLTR1 (0.45) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 | |
| SCHEMBL1551574 | 0.85 | CYSLTR1 (0.45) | PDE10ACYSLTR1CYP1A2CYSLTR2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053791-A1 | ONE-POT GRAFTING OF POLYMERS FROM ALCOHOLS AND BIOMASSES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| EP-2390250-B1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SK CHEMICALS CO LTD (KR) | 2015-08-12 | — | — | EP | claimed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | claimed |
| EP-2337124-B1 | Electrochemical gas development cell, in particular mercury-free hydrogen development cell | SIMATEC AG (CH) | 2014-05-07 | — | — | EP | claimed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | claimed |
| EP-2034998-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-03-18 | — | — | EP | claimed |
| WO-2008079427-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | claimed |
| WO-2025053791-A1 | ONE-POT GRAFTING OF POLYMERS FROM ALCOHOLS AND BIOMASSES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024081635-A2 | TARGETED QUINOCYANINE DYES FOR THE INTRAOPERATIVE DELINEATION OF CANCER MARGINS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-116410132-A | 8-hydroxyquinoline compound, preparation method thereof and application thereof in preparation of antitumor drugs | 广东工业大学 | 2023-07-11 | — | — | CN | disclosed |
| US-11688845-B2 | Method for passive metal activation and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-06-27 | — | — | US | disclosed |
| EP-3908269-A1 | COMBINATION IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIAL DISEASES | Janssen Pharmaceutica NV (BE) | 2021-11-17 | — | — | EP | disclosed |
| US-4634767-A | Method for preparing spiro(indoline)-type photochromic compounds | PPG INDUSTRIES, INC. (US) | 1987-01-06 | — | — | US | disclosed |
| US-4433017-A | IONIZABLE GROUP | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 1984-02-21 | — | — | US | disclosed |
| US-4242516-A | Fluorinated amphoteric surfactants | CIBA-GEIGY CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| US-4161602-A | Fluorinated amphoteric and cationic surfactants containing a pyridinium moiety | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4161590-A | Fluorinated amphoteric and cationic surfactants | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4069244-A | THIO-CARBOXYLIC ACIDS | CIBA-GEIGY CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | PDE10A 610/4885CYSLTR1 1148/4885CYP1A2 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.